420: Doublet with Mirvetuximab + Carboplatin in FRα-Low, -Medium, and -High Platinum-Sensitive Ovarian Cancer (Single-Arm Trial)
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.